MediPharm Labs Corp. (OTCQX: MEDIF) (TSX: LABS) a worldwide leader in specialized, investigation-driven pharmaceutical-high-quality cannabis extraction, distillation and derivative merchandise, right now announced it will provide cannabis concentrate merchandise in Denmark to two new healthcare cannabis buyers beneath two separate white-label agreements. These buyers will be serviced by each GMP authorized facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ very first provide agreements for the export of completed merchandise to Denmark.
Denmark granted individuals legal access to cannabis-primarily based medicinal merchandise two years ago as component of a 4-year pilot system. The system supplies individuals with secure solution access and national well being authorities with patient information that they can use to realize usage and efficacy. According to data complied by New Frontier Information and the Danish Ministry of Well being, more than two,one hundred individuals (mostly ladies amongst the ages of 42-64) received cannabis-primarily based medicinal merchandise from 429 prescribing physicians beneath this system in 2019.
“The express goal of establishing a multi-jurisdictional, GMP-certified production capability is to lead the worldwide cannabis marketplace for medicinal, wellness and adult use applications and these agreements represent a different step forward in realizing our ambitions,” mentioned Pat McCutcheon, CEO, MediPharm Labs. “Getting in on the ground floor of the Danish healthcare marketplace with new and revolutionary healthcare cannabis focused merchandise positions us for more development in Europe and adds to MediPharm Labs all-critical physique of information that we are leveraging to boost the style of our formulations for individuals and customers everywhere.”
Beneath the agreements, one particular which has an initial two-year term and the second a one particular-year term – each topic to renewal, MediPharm Labs will provide a complete variety of specially formulated CBD and THC cannabis oil merchandise that will be white-labeled for distribution.
MediPharm Labs anticipates delivery to its buyers to commence in October 2020, pending regulatory approval by applicable well being authorities.
GMP Certification Ignites Development for MediPharm Labs Australia
“Since the starting of 2020, MediPharm Labs Australia has secured many extremely appealing domestic and international provide agreements with higher high-quality partners, now such as new buyers in Denmark,” mentioned Warren Everitt, CEO, MediPharm Labs Australia. “This volume and the pace of new business enterprise wins are a clear and critical validation of our selection to make a GMP certified cannabis extraction facility provide chain for globe markets and a testament to MediPharm Labs increasing profile and reputation. We appear forward to ramping up production beneath all of these agreements.”
MediPharm Labs Australia received its Excellent Manufacturing Practice (“GMP”) certificate from the Therapeutic Goods Association in Might 2020, which enables it to sell cannabis APIs and completed merchandise to nations across the EU, such as Denmark. The Enterprise entered into its very first European white-label cannabis provide agreement that very same month with Therismos Restricted.
About Denmark’s Healthcare Cannabis Market place
Denmark launched its 4-year healthcare cannabis pilot system on January 1st, 20181. Post-harvest Excellent Manufacturing Processes (GMP) is essential for distribution of healthcare cannabis merchandise in Denmarktwo.
By means of the system, physicians can prescribe healthcare cannabis for all purposes and are guided by suggestions in 4 regions: discomfort brought on by several sclerosis, discomfort brought on by spinal cord harm, side effects from chemotherapy remedy and neuropathic discomfort that is due to brain, spinal cord or nerve harmthree. The recommendations published by the Danish Medicines Agency are primarily based on an comprehensive evaluation of literature as properly as assessments of: cannabis schemes in the Netherlands, Canada and Israel earlier cannabis drug approvals in Europe and the US and scientific proof by the National Academy of Sciences (USA, 2017).
About MediPharm Labs Corp.
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical high-quality cannabis oil and concentrates and sophisticated derivative merchandise using a Excellent Manufacturing Practices certified facility with ISO regular constructed clean rooms. MediPharm Labs has invested in an specialist, investigation-driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 key extraction lines for delivery of pure, trusted and precision -dosed cannabis merchandise for its buyers. By means of its wholesale and white label platforms, they formulate, customer-test, course of action, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based merchandise to domestic and international markets. As a worldwide leader, MediPharm Labs has completed industrial exports to Australia and is nearing commercialization of its Australian Extraction facility. MediPharm Labs Australia was established in 2017.
Sponsored Content material Release. Click for Complete Disclosure